Relia Tech/小鼠抗人PD-L2/100µg/101-M604
市场价：
¥5500.00
美元价：
3300.00
产品分类：
单克隆抗体
公司分类：
monoclonal_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | 101-M604 |
| Size | 100 µg |
| Price | 275 € |
| Category | Monoclonal Antibody |
| Clone Nr. | (#10B6) |
| Isotype | IgG2 |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml. |
| Stability and Storage | Lyophilized samples are stable for 2 years from date of receipt when stored at -20°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity. |
| Preparation | This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human PD-L2. |
| Antigen | recombinant human PD-L2 |
| Application | WB |
| Synonyms | PDCD1LG2; B7DC; Btdc; PDL2; CD273; PD-L2; PDCD1L2; bA574F11.2 |
| Description | T cells require a signal induced by the engagement of the T cell receptor and a “costimulatory” signal(s) through distinct T cell surface molecules for optimal T cell activation and tolerance. Members of the B7 superfamily of counter-receptors were identified by their ability to interact with costimulatory molecules found on the surface of T cells. Members of the B7 superfamily include B71 (CD80), B72 (CD86), B7H1 (PDL1), B7H2 (B7RP1), B7H3, and PDL2 (B7DC). B7 proteins are immunoglobulin (Ig) superfamily members with extracellular IgV-like and IgC-like domains and short cytoplasmic domains. Among the family members, they share from 20-40% amino acid (aa) sequence identity. The cloned human PDL2 cDNA encodes a 273 aa type I membrane precursor protein with a putative 20 aa signal peptide, a 201 aa extracellular region containing one V-like and one C-like Ig domain, a 24 aa transmembrane region, and a 28 aa cytoplasmic domain. The extracellular domains of mouse and human PDL2 share approximately 70% aa sequence identity. PDL2 is one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. The other identified ligand is PDL1. Human PDL1 and PDL2 share approximately 41% aa sequence identity and have similar functions. PDL2 is broadly expressed in tissues. Highest expression was detected by Northern blot analysis in heart, placenta, liver, pancreas, spleen, and lymph node. Lower amounts of expression were observed in lung, smooth muscle, and thymus. Expression of PDL2 on antigen presenting cell has been examined in detail. Resting B cells, monocytes and dendritic cells do not express PDL2, expression however can be induced by LPS or BCR activation in B cells, INFγ treatment in monocytes, or LPS plus IFN γ treatment of dendritic cells. PD L2 expression is also up regulated in a variety of tumor cell lines. On previously activated T cells, PDL2 interaction with PD1 inhibits TCRmediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. In contrast, a costimulatory function for the PDL2 on resting T cells activated with suboptimal TCR signals has also been reported. |
| Uniprot ID | Q9BQ51 |
| Protein RefSeq | NP_079515.2 |
| mRNA RefSeq | NM_025239.3 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
